Phaseline

Targets › ERBB3

ERBB3 (Receptor tyrosine-protein kinase erbB-3): drug programs, companies and trials

12 programs from 10 companies in 32 trials: 16 Phase 1, 14 Phase 2, 2 Phase 3; Oncology, Cardiovascular; next expected readout Dec 2026.

Tyrosine kinase receptor that, despite substitutions of key catalytic residues in the kinase domain, retains residual catalytic activity enabling autophosphorylation. Functions primarily as a heterodimer, preferentially partnering with ERBB2/HER2, which phosphorylates ERBB3 on specific tyrosine residues and provides the kinase activity required for downstream signaling. (UniProt, P21860)

Open in Phaseline: the race on ERBB3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Daiichi SankyoPatritumab Deruxtecan
Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor
ERBB3, TOP1Phase 3Nonsquamous Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer Metastatic; Advanced Solid Tumor; Non-Small Cell Lung Cancer (NSCLC) …Dec 2026
Merck & Co. (MSD)Patritumab Deruxtecan
Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor
ERBB3, TOP1Phase 3Breast Neoplasms; Non-small Cell Lung Cancer; Gastroesophageal Junction; Gastrointestinal Cancer …May 2028
Partner TherapeuticsZenocutuzumab (MCLA-128)
ErbB-2/ErbB-3 heterodimer inhibitor
ERBB2, ERBB3Phase 2Solid Tumours Harboring NRG1 FusionDec 2026
Fudan UniversitySHR-A2009
HER3-directed antibody-drug conjugate
ERBB3Phase 2Advanced Breast CancerSep 2027
Roswell Park Cancer InstituteAnti-HER2/HER3 Dendritic Cell Vaccine
Dendritic cell vaccine targeting HER2 and HER3
ERBB2, ERBB3Phase 2Anatomic Stage IV Breast Cancer AJCC v8May 2028
Salubris BiotherapeuticsJK07
Anti-HER3 antibody fused with EGF-domain of Neuregulin-1b
ERBB3Phase 2Heart Failure With Reduced Ejection Fraction–
Shanghai Institute Of Biological ProductsSIBP-03
HER3 monoclonal antibody
ERBB3Phase 2Head and Neck Squamous Cell Carcinoma–
UNICANCERSapitinib (AZD8931)
Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-3 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, ERBB3, EGFRPhase 2Metastatic Breast Cancer–
Hummingbird BioscienceHMBD-501
HER3-targeted antibody-drug conjugate
ERBB3Phase 1Melanoma (Skin)Jul 2027
Hummingbird BioscienceHMBD-001
Anti-HER3 monoclonal antibody
ERBB3Phase 1Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Bladder CancerDec 2027
Herbert LyerlypING-hHER3FL
Plasmid DNA vaccine encoding full-length human HER3 (ErbB3) protein
ERBB3Phase 1Advanced CancerMar 2030
Shanghai Institute Of Biological ProductsSIBP-A13
HER3-targeting antibody-drug conjugate
ERBB3Phase 1Advanced Solid Tumor–

Conditions

Breast Neoplasms (3) Advanced Solid Tumor (2) Non-Small Cell Lung Cancer (NSCLC) (2) Metastatic Breast Cancer (2) Gastroesophageal Junction (2) Nonsquamous Non-small Cell Lung Cancer (1) Non-Small Cell Lung Cancer Metastatic (1) Hormone Receptor Positive (1) Heart Failure With Reduced Ejection Fraction (1) Head and Neck Squamous Cell Carcinoma (1) Melanoma (Skin) (1) Non-small Cell Lung Cancer (1)

Modalities

small molecule (4), mixed (4), antibody (2), protein or peptide (2)

Companies

Shanghai Institute Of Biological Products (2) Hummingbird Bioscience (2) Daiichi Sankyo (1) Salubris Biotherapeutics (1) UNICANCER (1) Merck & Co. (MSD) (1) Partner Therapeutics (1) Roswell Park Cancer Institute (1) Fudan University (1) Herbert Lyerly (1)

Related targets

ERBB2 (3) TOP1 (2) EGFR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.